Originally published by our sister publication Specialty Pharmacy Continuum
Sarah Alwardt, MEng, PhD
NATIONAL HARBOR, Md.—Real-world data on clinical outcomes, coupled with other patient-focused measures, can guide pharmaceutical companies and payors when navigating the drug development and coverage review process, according to speakers at the Academy of Managed Care Pharmacy (AMCP) Nexus 2022 meeting.
In the case of investigational agents, new drugs still need to be safe